Lomela Cream is a topical dermatological formulation containing Hydroquinone (2% w/w), Mometasone Furoate (0.1% w/w), and Tretinoin (0.025% w/w), designed for the treatment of hyperpigmentation disorders such as melasma, dark spots, and post-inflammatory hyperpigmentation. Hydroquinone acts as a depigmenting agent by inhibiting tyrosinase, thereby reducing melanin synthesis and facilitating skin lightening. Mometasone, a potent corticosteroid, provides anti-inflammatory and immunosuppressive effects that help reduce erythema, swelling, and irritation associated with pigmentary conditions. Tretinoin, a retinoid, promotes epidermal cell turnover and enhances the penetration of hydroquinone, accelerating the resolution of hyperpigmented lesions. Lomela Cream should be applied once daily to the affected area, preferably at night, under medical supervision due to the potential for adverse effects such as skin irritation, dryness, and corticosteroid-induced skin thinning with prolonged use. It is contraindicated in patients with hypersensitivity to any of its components, pregnancy, or active skin infections. Patients are advised to use sunscreen and avoid excessive sun exposure during treatment to prevent further pigmentation. Lomela Cream offers a synergistic approach to managing pigmentary disorders, combining depigmentation, anti-inflammatory, and keratolytic actions for optimal therapeutic outcomes.